Emerging data on optimal adjuvant endocrine therapy: Breast international group trial 1-98/MA.17

Clinical Breast Cancer

Volumn 6, Issue SUPPL. 2, 2006, Pages

  Wardley, Andrew M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Anastrozole; Aromatase inhibitors; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; NITRILE; PROGESTERONE RECEPTOR; TRIAZOLE DERIVATIVE;

ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; CANCER STAGING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CANCER; FOLLOW UP; FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MYALGIA; OSTEOPOROSIS; POSTMENOPAUSE; RANDOMIZATION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VAGINA BLEEDING; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; DRUG ADMINISTRATION; FEMALE; MIDDLE AGED; REVIEW;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TRIAZOLES;

EID: 33645944352     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.s.003     Document Type: Article

References (22)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
2. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 2004; 9:126-136.
3. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18:3748-3757.
4. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18:3758-3767.
5. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21:2101-2109.
6. Paridaens R, Therasse P, Dirix L. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - a randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Oncol 2004; 23:6 (Abstract #515).
7. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
8. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757.
9. Boccardo F, Rubagotti A, Puntoni M. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. J Clin Oncol 2005; 23(16 suppl):10s (Abstract #526).
10. Coombes RC, Hall E, Snowdon CF. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen - updated survival analysis. Breast Cancer Res Treat 2004; 88(suppl 1):S7 (Abstract #3).
11. Jakesz R, Kaufmann M, Gnant M. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG trial 8 and the ARNO 95 trial. Breast Cancer Res Treat 2004; 88(suppl 1):S7 (Abstract #2).
12. Jakesz R, Gnant M, Greil R. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Presented at: The 28th Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, TX Abstract #13.
13. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-1271.
14. Jakesz R, Samonigg H, Greil R. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group trial 6a (ABCSG-6a). J Clin Oncol 2005; 23(16 suppl):10s (Abstract #527).
15. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-629.
16. Ingle JN, Goss PE, Tu D. Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17. Breast Cancer Res Treat 2005; 94(suppl 1):S11 (Abstract #17).
17. Goss PE, Ingle JN, Palmer MJ. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. Presented-at: The 28th Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, TX. Abstract #16.
18. Thurlimann B. BIG 1-98: a prospective randomized double-blind double-dummy phase III study to evaluate letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer Presented at: Primary Therapy of Early Breast Cancer; January 26-29, 2005; St Gallen, Switzerland.
19. Thurlimann B, Keshaviah A, Mouridsen H. BIG 1-98: randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. J Clin Oncol 2005; 23(16 suppl):6s (Abstract #511).
20. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139.
21. Viale G, Regan M, Dell'Orto P. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Presented at: The 28th Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, TX. Abstract #44.
22. Dowsett M. Analysis of time to recurrence in the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003; 82(suppl 1):S7 (Abstract #4).